-
FDA warns manufacturers and preparers of pharmaceutical products containing glycerin of the importance of assuring that the glycerin used is not contaminated with diethylene glycol.
Food and Drug Administration (Pharmacology) - Tue, 8 May 2007
http://www.fda.gov
-
Most diseases are caused by malfunctions in the body´s complex protein machinery. The next generation of drugs will be designed on the basis of 3D protein models that scientists are creating.
Karolinska Institutet (Pharmacology) - Wed, 28 March 2007
http://ki.se/ki/jsp/polopoly.jsp?d=130&l=en
-
In the treatment of hyponatremia the only available antagonist of vasopressin receptors has been recently used: conivaptan, an intravenous drug approved by FDA for the hospital treatment of hyponatremic euvolemic subjects.
MedNews (Pharmacology) - Tue, 27 March 2007
http://mn.medsurfnews.com/
-
FDA requested that manufacturers of sedative-hypnotic drug products strengthen their product labeling to inform providers and patients of serious potential risks, including severe allergic reactions and complex sleep-related behaviors, which may include sleep-driving.
Food and Drug Administration (Pharmacology) - Thu, 15 March 2007
http://www.fda.gov
-
More than twenty technology companies are responding to a call to support the fight against counterfeit medicines spearheaded by the International Medical Products Anti-Counterfeiting Taskforce (IMPACT) set up by the World Health Organization (WHO) and partners.
World Health Organization (Pharmacology) - Thu, 15 March 2007
http://www.who.int
-
One third of the drugs tested separately in children had different effects than in adults; some were more toxic, and others were completely ineffective.
Medscape (Pharmacology) - Wed, 7 February 2007
http://www.medscape.com
-
FDA informed consumers and healthcare professionals of the potential hazards of using skin numbing products containing topical anesthetic drugs such as lidocaine, tetracaine, benzocaine, and prilocaine in a cream, ointment, or gel.
Food and Drug Administration (Pharmacology) - Wed, 7 February 2007
http://www.fda.gov
-
In 1997, Congress authorized the US Food and Drug Administration (FDA) to grant 6-month extensions of marketing rights through the Pediatric Exclusivity Program if industry sponsors complete FDA-requested pediatric trials.
Journal of the American Medical Association (Pharmacology) - Tue, 6 February 2007
http://jama.ama-assn.org/
-
Three deaths in U.S. infants aged less than 12 months associated with cough and cold medications.
Food and Drug Administration (Pharmacology) - Tue, 16 January 2007
http://www.fda.gov